Update of the National Surgical Adjvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely because it increased endometrial cancer and thromboembolic events. The FDA appro...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Vogel, Victor G., Costantino, Joseph P., Wickerham, D. Lawrence, Cronin, Walter M., Cecchini, Reena S., Atkins, James N., Bevers, Therese B., Fehrenbacher, Louis, Pajon, Eduardo R., Wade, James L., Robidoux, Andre, Margolese, Richard G., James, Joan, Runowicz, Carolyn D., Ganz, Patricia A., Reis, Steven E., McCaskill-Stevens, Worta, Ford, Leslie G., Jordan, V. Craig, Wolmark, Norman
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935331/
https://ncbi.nlm.nih.gov/pubmed/20404000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0076
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires